| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 1998302 | Molecular Genetics and Metabolism | 2014 | 8 Pages |
•Treatments for mitochondrial diseases are limited in clinical practice•There are promising experimental therapeutic strategies for this group of diseases•The challenge is their translation into safe and effective therapies for patients
Mitochondrial diseases are a heterogeneous group of disorders resulting from primary dysfunction of the respiratory chain due to both nuclear and mitochondrial DNA mutations. The wide heterogeneity of biochemical dysfunctions and pathogenic mechanisms typical of this group of diseases has hindered therapy trials; therefore, available treatment options remain limited.Therapeutic strategies aimed at increasing mitochondrial functions (by enhancing biogenesis and electron transport chain function), improving the removal of reactive oxygen species and noxious metabolites, modulating aberrant calcium homeostasis and repopulating mitochondrial DNA could potentially restore the respiratory chain dysfunction.The challenge that lies ahead is the translation of some promising laboratory results into safe and effective therapies for patients.In this review we briefly update and discuss the most feasible therapeutic approaches for mitochondrial diseases.
